New drug combo shows promise for tough blood cancers in early trial
NCT ID NCT05665530
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. The study is now complete, and results will help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
86 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * Histologically or cytologically confirmed diagnosis of aggressive B-cell lymphoma subtypes, MCL, MZL, or CLL/SLL (including Richter's syndrome) based on local testing, or TCL (monotherapy only), AML, CMML, MDS, or MDS/MPN overlap syndrome that have relapsed or become refractory to or be ineligible for standard-of-care therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of \< 2. * Adequate organ function (hematology, renal, and hepatic) * Echocardiogram (or multigated acquisition \[MUGA\] scan) indicating a left ventricular ejection fraction of ≥ 50% Exclusion Criteria: * Have active central nervous system involvement by malignancy, uncontrolled intercurrent illnesses, and active infections requiring systemic therapy * Have undergone HSCT within the last 90 days or have graft versus host disease (GvHD) Grade \> 1 at study entry * Have severe pulmonary disease with hypoxemia * History of another malignancy except for adequately treated non-melanoma skin cancer or lentigo maligna, superficial bladder cancer, and carcinoma in situ of the cervix without evidence of disease, and asymptomatic prostate cancer without known metastatic disease and no requirement for therapy * Concurrent treatment or within 15 days of starting study treatment with strong CYP3A4 inhibitors * Prior exposure to a CDK9 inhibitor * Wait at least 5 half-lives of the agent or 14 days after their investigational or approved therapies before start of study treatment, whichever is shorter * Mean corrected QT interval of \> 470 msec following triplicate ECG measurement or history of long QT syndrome * T-Cell leukemias
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817, United States
-
Austin Health
Heidelberg, Victoria, 3084, Australia
-
Centre Léon Bérard
Lyon, 69373 Cedex 08, France
-
City of Hope
Duarte, California, 91010, United States
-
Claude Huriez Hospital
Lille, 59000, France
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Ente Ospedaliero Cantonale (EOC) lstituto Oncologico della Svizzera italiana (IOSl)- Ospedale San Giovanni (ORBV)
Bellinzona, Canton Ticino, 6500, Switzerland
-
Hopital Henri Mondor
Créteil, 94010, France
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola
Bologna, 40138, Italy
-
Institut Curie
Saint-Cloud, 92210, France
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Keimyung_University Dongsan Hospital
Daegu, 42601, South Korea
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Linear Clinical Research Ltd
Perth, Western Australia, 6009, Australia
-
Monash Health
Melbourne, Victoria, 3168, Australia
-
Ospedale Santa Maria delle Croci - AUSL della Romagna
Ravenna, 48121, Italy
-
Pratia MCM Krakow
Krakow, Lesser Poland Voivodeship, 30-727, Poland
-
Samsung Medical Center
Seoul, 06351, South Korea
-
The Leeds Teaching Hospitals NHS Trust, St James University Hospital
Leeds, West Yorkshire, LS9 7TF, United Kingdom
-
Universitatsklinikum Koln, Klinik I fur lnnere Medizin
Cologne, North Rhine-Westphalia, 50937, Germany
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
-
lnje University Busan Paik Hospital
Busan, 47392, South Korea
-
lstituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST
Meldola, FC, 47014, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a liposomal drug combo improve AML treatment for older adults?
- Can a CDK8/CDK19 blocker help when leukemia and MDS return?
- Off-the-Shelf Gene-Edited immune cells tested against Hard-to-Treat lymphoma
- Can an Anti-Inflammation drug make AML chemotherapy work better?
- Proton beams vs. X-Rays: can a pricier radiation spare hearts and prevent second cancers?
- New drug joins standard chemotherapy in fight against B-Cell lymphoma